IP Library › Granted Patent US 12,391,920
Granted Patent B2
US 12,391,920 · App. 18/819,435 · Granted Aug 19, 2025

Models of tauopathy

Inventors: Marine Prissette (Brooklyn, NY); Matthew Koss (Pleasantville, NY); Mathieu Desclaux (Brooklyn, NY); John McWhirter (Hastings-on-Hudson, NY); Arijit Bhowmick (Astoria, NY); David Frendewey (New York, NY); Brian Zambrowicz (Sleepy Hollow, NY); Claudia Racioppi (New York, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
C12N5/0619A61K9/0019A61K48/0058C12N15/113A01K2267/0312A01K2267/0318C12N2310/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,391,920
App. No.
18/819,435
Granted
Aug 19, 2025
Kind
B2
Abstract

BANF1, PPP2CA, and ANKLE2 were identified as genes that promote tau aggregation when disrupted. Improved tauopathy models such as cells, tissues, or animals having mutations in or inhibition of expression of BANF1 and/or PPP2CA and/or ANKLE2 are provided. Methods of using such improved tauopathy models for assessing therapeutic candidates for the treatment of a tauopathy, methods of making the improved tauopathy models, and methods of accelerating or exacerbating tau aggregation in a tauopathy model are also provided.

Claims (98)

1. A rodent, an animal tissue, or a population of animal cells comprising:

(a) an exogenous human microtubule-associated protein tau coding sequence in a plurality of cells,

wherein the exogenous human microtubule-associated protein tau comprises a tauopathy-associated mutation,

wherein the exogenous human microtubule-associated protein tau coding sequence is expressed in the plurality of cells, and

wherein the plurality of cells are neuronal cells; and

(b) (i) a genetic modification in one or both of BANF1 and ANKLE2 that reduces expression of the one or both of BANF1 and ANKLE2, respectively, in the plurality of cells compared to a plurality of cells without the genetic modification and/or (ii) one or more agents that reduce expression of one or both of BANF1 and ANKLE2 in the plurality of cells compared to a plurality of cells without the one or more agents, and

wherein at least one sign or symptom of tauopathy is increased in the rodent, the animal tissue or the population of animal cells relative to a rodent, an animal tissue, or a population of animal cells that does not comprise the genetic modification in the one or both of BANF1 and ANKLE2 or does not comprise the one or more agents that reduce expression of one or both of BANF1 and ANKLE2, wherein the at least one sign or symptom comprises:

(I) tau hyperphosphorylation or tau aggregation; and/or

(II) increased tau and/or phospho-tau in an insoluble fraction following cell fractionation, increased phospho-tau in the somatodendritic compartment of neurons, increased phospho-tau in the perinuclear region of neurons, decreased nuclear pore complex protein Nup98-Nup96 (Nup98) nuclear-to-cytoplasmic ratio in neurons, decreased GTP-binding nuclear protein Ran (Ran) nuclear-to-cytoplasmic ratio in neurons, or decreased Ran GTPase-activating protein 1 (RanGAP1) nuclear-to-cytoplasmic ratio in neurons.

2. The rodent, the animal tissue, or the population of animal cells of claim 1 , wherein:

(I) the exogenous human microtubule-associated protein tau coding sequence is genomically integrated; and/or

(II) the exogenous human microtubule-associated protein tau coding sequence comprises a complementary DNA (cDNA) sequence; and/or

(III) the exogenous human microtubule-associated protein tau coding sequence is codon-optimized for expression in the rodent, the animal tissue, or the population of animal cells; and/or

(IV) the exogenous human microtubule-associated protein tau coding sequence is operably linked to a heterologous promoter, a mouse prion protein promoter, a neuron-specific promoter, or a synapsin-1 promoter.

3. The rodent, the animal tissue, or the population of animal cells of claim 1 , wherein:

(I) the tauopathy-associated mutation comprises a P301S mutation or wherein the exogenous human microtubule-associated protein tau comprises the sequence set forth in SEQ ID NO: 98; or

(II) the tauopathy-associated mutation comprises an A152T/P301L/S320F triple mutation or wherein the exogenous human microtubule-associated protein tau coding sequence comprises the sequence set forth in SEQ ID NO: 83 or the exogenous human microtubule-associated protein tau comprises the sequence set forth in SEQ ID NO: 84.

4. The rodent, the animal tissue, or the population of animal cells of claim 1 , wherein the rodent, the animal tissue, or the population of animal cells comprises the genetic modification in the one or both of BANF1 and ANKLE2 that reduces expression of the one or both of BANF1 and ANKLE2, respectively, in the plurality of cells.

5. The rodent, the animal tissue, or the population of animal cells of claim 1 , wherein the rodent, the animal tissue, or the population of animal cells comprises the one or more agents that reduce expression of the one or both of BANF1 and ANKLE2 in the plurality of cells, wherein the one or more agents comprise:

(I) a nuclease agent targeting BANF1 or ANKLE2 or a nucleic acid encoding the nuclease agent, wherein the nuclease agent is a Zinc Finger Nuclease (ZFN), a Transcription Activator-Like Effector Nuclease (TALEN), or a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) protein and a guide RNA;

(II) a transcriptional repressor targeting BANF1 or ANKLE2 or a nucleic acid encoding the transcriptional repressor, wherein the transcriptional repressor comprises a guide RNA and a catalytically inactive Cas protein fused to a transcriptional repressor domain; or

(III) an antisense oligonucleotide or an RNAi agent targeting BANF1 or ANKLE2 or a nucleic acid encoding the antisense oligonucleotide or the RNAi agent.

6. The rodent, the animal tissue, or the population of animal cells of claim 5 , wherein the nuclease agent is the Cas protein and the guide RNA, wherein the Cas protein is a Cas9 protein, and wherein the Cas protein is a catalytically active Cas protein.

7. The rodent, the animal tissue, or the population of animal cells of claim 6 , wherein:

(I) the guide RNA targets mouse Banf1 and comprises any one of the sequences set forth in SEQ ID NOS: 44-46 or the guide RNA targets human BANF1 and comprises any one of the sequences set forth in SEQ ID NOS: 27-30; or

(II) the guide RNA targets mouse Ankle2 and comprises any one of the sequences set forth in SEQ ID NOS: 50-52 or the guide RNA targets human ANKLE2 and comprises the sequence set forth in SEQ ID NO: 38.

8. The rodent, the animal tissue, or the population of animal cells of claim 5 , wherein:

(I) the antisense oligonucleotide comprises the sequence set forth in any one of SEQ ID NOS: 105-126, 169-236, or 279-324, or

(II) the antisense oligonucleotide comprises the sequence set forth in any one of SEQ ID NOS: 105, 106, 110-113, 115, 120-122, 124, 125, 169, 171-173, 175, 177, 181-184, 187, 194, 197, 211, 213, 215, 216, 220-223, 225, 230-232, 234, 235, 279, 281-283, 285, 287, 291-294, 297, 304, 307, 321, and 323; and

wherein the antisense oligonucleotide comprises one or more phosphorothioate linkages and/or one or more 2′-methoxyethyl modified bases, or wherein the antisense oligonucleotide is a 5-10-5 gapmer comprising a phosphorothioate backbone, a 5′ wing of 2′-methoxyethyl modified bases, a central 10-nucleotide core of DNA, and a 3′ wing of 2′-methoxyethyl modified bases.

9. The population of animal cells of claim 1 , wherein:

(I) the cells are human cells, mouse cells, or rat cells; and/or

(II) the cells comprise neuronal cells, wherein the neuronal cells comprise neurons derived from human induced pluripotent stem cells, neurons derived from mouse embryonic stem cells, or primary mouse neurons.

10. The animal tissue of claim 1 , wherein:

(I) the animal is a mouse or a rat; and/or

(II) the tissue is a nervous system tissue, wherein the tissue comprises a brain slice.

11. The rodent of claim 1 , wherein:

(I) the genetic modification in one or both of BANF1 and ANKLE2 is in a plurality of neuronal cells and/or wherein the one or more agents that reduce expression of one or both of BANF1 and ANKLE2 are in the plurality of neuronal cells, wherein the plurality of neuronal cells are in the hippocampus; and/or

(II) wherein the rodent is a mouse, and the mouse is a PS19 transgenic mouse further comprising the genetic modification in the one or both of BANF1 and ANKLE2 that reduces expression of the one or both of BANF1 and ANKLE2, respectively, in the plurality of cells and/or further comprising the one or more agents that reduce expression of one or both of BANF1 and ANKLE2 in the plurality of cells,

wherein the PS19 transgenic mouse expresses mutant human microtubule-associated protein tau driven by a mouse prion protein promoter.

12. A method for assessing a therapeutic candidate for the treatment of a tauopathy, comprising:

(a) administering a candidate agent to the rodent, the animal tissue, or the population of animal cells of claim 1 ;

(b) performing one or more assays to determine if the candidate agent has an effect on one or more signs or symptoms associated with the tauopathy; and

(c) identifying the candidate agent that has an effect on the one or more signs or symptoms associated with the tauopathy as a therapeutic candidate.

13. The method of claim 12 , wherein the one or more signs or symptoms comprise:

(I) tau hyperphosphorylation or tau aggregation; and/or

(II) increased tau and/or phospho-tau in an insoluble fraction following cell fractionation, increased phospho-tau in the somatodendritic compartment of neurons, increased phospho-tau in the perinuclear region of neurons, decreased nuclear pore complex protein Nup98-Nup96 (Nup98) nuclear-to-cytoplasmic ratio in neurons, decreased GTP-binding nuclear protein Ran (Ran) nuclear-to-cytoplasmic ratio in neurons, or decreased Ran GTPase-activating protein 1 (RanGAP1) nuclear-to-cytoplasmic ratio in neurons.

14. The method of claim 12 , wherein the candidate agent is administered to the rodent, is administered to the animal tissue ex vivo, or is administered to the population of animal cells in vitro.

15. A method of making the rodent, the animal tissue, or the population of animal cells of claim 1 , comprising:

(I) (a) introducing the one or more agents that reduce expression of one or both of BANF1 and ANKLE2 into a rodent, an animal tissue, or a population of animal cells that comprises the exogenous human microtubule-associated protein tau coding sequence; and

(b) screening the rodent, the animal tissue, or the population of animal cells to confirm the presence of the one or more agents; or

(II) (a) introducing into a rodent, an animal tissue, or a population of animal cells:

(i) an exogenous human microtubule-associated protein tau coding sequence; and

(ii) the one or more agents that reduce expression of one or both of BANF1 and ANKLE2; and

(b) screening the rodent, the animal tissue, or the population of animal cells to confirm the presence of the one or more agents and the exogenous human microtubule-associated protein tau coding sequence.

16. The method of claim 15 , wherein:

(I) the exogenous human microtubule-associated protein tau coding sequence is delivered via adeno-associated virus, lentivirus, or lipid nanoparticle; and/or

(II) the one or more agents are delivered via adeno-associated virus, lentivirus, or lipid nanoparticle; and/or

(III) the method is for making the rodent, and the one or more agents are administered to the rodent by intrathecal injection, intracranial injection, intracerebroventricular injection, or stereotactic injection into the brain.

17. A method for accelerating or exacerbating tau aggregation in a tauopathy model rodent, a tauopathy model animal tissue, or a tauopathy model population of animal cells, comprising introducing into the tauopathy model rodent, the tauopathy model animal tissue, or the tauopathy model population of animal cells one or more agents that reduce expression of one or both of BANF1 and ANKLE2 compared to a rodent, an animal tissue, or a population of animal cells without the one or more agents,

wherein the tauopathy model rodent, the tauopathy model animal tissue, or the tauopathy model population of animal cells comprises an exogenous human microtubule-associated protein tau coding sequence in a plurality of cells, and

wherein the exogenous human microtubule-associated protein tau comprises a tauopathy-associated mutation,

wherein the exogenous human microtubule-associated protein tau coding sequence is expressed in the plurality of cells,

wherein the plurality of cells are neuronal cells, and

wherein at least one sign or symptom of tauopathy is increased in the rodent, the animal tissue, or the population of animal cells relative to a rodent, an animal tissue, or a population of animal cells that does not comprise the one or more agents that reduce expression of one or both of BANF1 and ANKLE2, wherein the at least one sign or symptom comprises:

(I) tau hyperphosphorylation or tau aggregation; and/or

(II) increased tau and/or phospho-tau in an insoluble fraction following cell fractionation, increased phospho-tau in the somatodendritic compartment of neurons, increased phospho-tau in the perinuclear region of neurons, decreased nuclear pore complex protein Nup98-Nup96 (Nup98) nuclear-to-cytoplasmic ratio in neurons, decreased GTP-binding nuclear protein Ran (Ran) nuclear-to-cytoplasmic ratio in neurons, or decreased Ran GTPase-activating protein 1 (RanGAP1) nuclear-to-cytoplasmic ratio in neurons.

18. The method of claim 17 , wherein:

(I) the exogenous human microtubule-associated protein tau coding sequence is genomically integrated; and/or

(II) the exogenous human microtubule-associated protein tau coding sequence comprises a complementary DNA (cDNA) sequence; and/or

(III) the exogenous human microtubule-associated protein tau coding sequence is codon-optimized for expression in the rodent, the animal tissue, or the population of animal cells; and/or

(IV) the exogenous human microtubule-associated protein tau coding sequence is operably linked to a heterologous promoter, a mouse prion protein promoter, a neuron-specific promoter, or a synapsin-1 promoter.

19. The method of claim 18 , wherein:

(I) the tauopathy-associated mutation comprises a P301S mutation or wherein the exogenous human microtubule-associated protein tau comprises the sequence set forth in SEQ ID NO: 98; or

(II) the tauopathy-associated mutation comprises an A152T/P301L/S320F triple mutation or wherein the exogenous human microtubule-associated protein tau coding sequence comprises the sequence set forth in SEQ ID NO: 83 or the exogenous human microtubule-associated protein tau comprises the sequence set forth in SEQ ID NO: 84.

20. The method of claim 17 , wherein the one or more agents comprise:

(I) a nuclease agent targeting BANF1 or ANKLE2 or a nucleic acid encoding the nuclease agent, wherein the nuclease agent is a Zinc Finger Nuclease (ZFN), a Transcription Activator-Like Effector Nuclease (TALEN), or a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated (Cas) protein and a guide RNA;

(II) a transcriptional repressor targeting BANF1 or ANKLE2 or a nucleic acid encoding the transcriptional repressor, wherein the transcriptional repressor comprises a guide RNA and a catalytically inactive Cas protein fused to a transcriptional repressor domain; or

(III) an antisense oligonucleotide or an RNAi agent targeting BANF1 or ANKLE2 or a nucleic acid encoding the antisense oligonucleotide or the RNAi agent.

21. The method of claim 20 , wherein the nuclease agent is the Cas protein and the guide RNA, wherein the Cas protein is a Cas9 protein, and wherein the Cas protein is a catalytically active Cas protein.

22. The method of claim 21 , wherein:

(I) the guide RNA targets mouse Banf1 and comprises any one of the sequences set forth in SEQ ID NOS: 44-46 or the guide RNA targets human BANF1 and comprises any one of the sequences set forth in SEQ ID NOS: 27-30; or

(II) the guide RNA targets mouse Ankle2 and comprises any one of the sequences set forth in SEQ ID NOS: 50-52 or the guide RNA targets human ANKLE2 and comprises the sequence set forth in SEQ ID NO: 38.

23. The method of claim 20 , wherein:

(I) the antisense oligonucleotide comprises the sequence set forth in any one of SEQ ID NOS: 105-126, 169-236, or 279-324; or

(II) the antisense oligonucleotide comprises the sequence set forth in any one of SEQ ID NOS: 105, 106, 110-113, 115, 120-122, 124, 125, 169, 171-173, 175, 177, 181-184, 187, 194, 197, 211, 213, 215, 216, 220-223, 225, 230-232, 234, 235, 279, 281-283, 285, 287, 291-294, 297, 304, 307, 321, and 323; and

wherein the antisense oligonucleotide comprises one or more phosphorothioate linkages and/or one or more 2′-methoxyethyl modified bases, or wherein the antisense oligonucleotide is a 5-10-5 gapmer comprising a phosphorothioate backbone, a 5′ wing of 2′-methoxyethyl modified bases, a central 10-nucleotide core of DNA, and a 3′ wing of 2′-methoxyethyl modified bases.

24. The method of claim 17 , wherein:

(I) the one or more agents are delivered via adeno-associated virus, lentivirus, or lipid nanoparticle; and/or

(II) the one or more agents are administered to the rodent by intrathecal injection, intracranial injection, intracerebroventricular injection, or stereotactic injection into the brain.

25. The method of claim 17 , wherein the cells are in vivo or in vitro, and wherein:

(I) the cells are human cells, mouse cells, or rat cells; and/or

(II) the cells comprise neuronal cells, wherein the neuronal cells comprise neurons derived from human induced pluripotent stem cells, neurons derived from mouse embryonic stem cells, or primary mouse neurons.

26. The method of claim 17 , wherein the tissue is in vivo or ex vivo, and wherein:

(I) the animal is a mouse or a rat; and/or

(II) the tissue is a nervous system tissue, wherein the tissue comprises a brain slice.

27. The method of claim 17 , wherein the rodent is a mouse, and the mouse is a PS19 transgenic mouse further comprising the one or more agents that reduce expression of one or both of BANF1 and ANKLE2,

wherein the PS19 transgenic mouse expresses mutant human microtubule-associated protein tau driven by a mouse prion protein promoter.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2025
From: RACIOPPI, CLAUDIA; PRISSETTE, MARINE; KOSS, MATTHEW; DESCLAUX, MATHIEU; MCWHIRTER, JOHN; BHOWMICK, ARIJIT; FRENDEWEY, DAVID; ZAMBROWICZ, BRIAN
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 070583/0954 →
Continuity (4)
Continuation 18502516 · Nov 6, 2023
Division 16900432 · Jun 12, 2020
Provisional Application 62861553 · Jun 14, 2019
Related Publication 20240409891A1 · Dec 12, 2024
References Cited (106)
US 9910048B2 · Diamond et al. · 2018 [cited by applicant]
US 11001829B2 · Zhang et al. · 2021 [cited by applicant]
US 11781131B2 · Prissette et al. · 2023 [cited by applicant]
US 11845930B2 · Fury et al. · 2023 [cited by applicant]
US 11845931B2 · Prissette et al. · 2023 [cited by applicant]
US 11845957B2 · Prissette et al. · 2023 [cited by applicant]
US 12110502B2 · Prissett et al. · 2024 [cited by applicant]
US 20140031291A1 · Mohler et al. · 2014 [cited by applicant]
US 20140162306A1 · Robitzki et al. · 2014 [cited by applicant]
US 20140286954A1 · Moe et al. · 2014 [cited by applicant]
US 20160272965A1 · Zhang et al. · 2016 [cited by applicant]
US 20180291370A1 · Gersbach et al. · 2018 [cited by applicant]
US 20180305704A1 · Zhang · 2018 [cited by applicant]
US 20190032155A1 · Gong et al. · 2019 [cited by applicant]
US 20190284572A1 · Hunt et al. · 2019 [cited by applicant]
US 20190365924A1 · Conway et al. · 2019 [cited by applicant]
US 20190390195A1 · Tondera et al. · 2019 [cited by applicant]
US 20200165601A1 · Zhang et al. · 2020 [cited by applicant]
US 20200299681A1 · Prissette et al. · 2020 [cited by applicant]
US 20200299682A1 · Prissette et al. · 2020 [cited by applicant]
US 20210009949A1 · Prissette et al. · 2021 [cited by applicant]
US 20230416728A1 · Prissette et al. · 2023 [cited by applicant]
US 20240076613A1 · Prissette et al. · 2024 [cited by applicant]
EP 3011033B1 · 2020 [cited by applicant]
WO WO2014089104A1 · 2014 [cited by applicant]
WO WO2016205711A1 · 2016 [cited by applicant]
WO WO2017015637A1 · 2017 [cited by applicant]
WO WO2017100343A1 · 2017 [cited by applicant]
WO WO2018157769A1 · 2018 [cited by applicant]
WO WO2018224531A1 · 2018 [cited by applicant]
WO WO2019010384A1 · 2019 [cited by applicant]
WO WO2019028032A1 · 2019 [cited by applicant]
WO WO2019183123A1 · 2019 [cited by applicant]
WO WO2019237069A1 · 2019 [cited by applicant]
WO WO2019246203A1 · 2019 [cited by applicant]
WO WO2020190927A1 · 2020 [cited by applicant]
WO WO2020190932A1 · 2020 [cited by applicant]
WO WO2020252340A1 · 2020 [cited by applicant]
“The 96th Annual Meeting of the Physiological Society of Japan,” Journal of Physiological Sciences, Springer Japan KK, 69(Suppl 1), (2019). [cited by applicant]
Adli, “The CRISPR tool kit for genome editing and beyond,” Nat. Commun., 9(1):1911, 13 pages, (2018). [cited by applicant]
Anders et al., “Differential expression analysis for sequence count data,” Genome Biol., 11:R106, pp. 1-12, (2010). [cited by applicant]
Anonymous, “Identification of genetic regulators for intracellular aggregation by genome-wide CRISPR screening,” 2016 Fiscal Year Annual Research Report, The University of Tokyo, Kaken, 2 pages, (2018). [cited by applicant]
Anonymous, Abstracts: Oral Presentations, Cell Biology, ASCB Annual Meeting, 84 pages, (2016). [cited by applicant]
Asencio et al., “Coordination of Kinase and Phosphatase Activities by Lem4 Enables Nuclear Envelope Reassembly during Mitosis,” Cell, 150(1):122-135, (2012). [cited by applicant]
Bajar et al., “A Guide to Fluorescent Protein FRET Pairs,” Sensors (Basel), 16:E1488, pp. 1-24, (2016). [cited by applicant]
Bennett et al., “Enhanced Tau Aggregation in the Presence of Amyloid β,” Am. J. Pathol., 187(7):1601-1612, (2017). [cited by applicant]
Boettcher, et al., “Choosing the Right Tool for th eJob: RNAi, Talen, or CRISPR,” Mol. Cell 58(4):575-585, (May 2014). [cited by applicant]
Brandt et al., “Tau alteration and neuronal degeneration in tauopathies: mechanisms and models,” Biochim. Biophys. Acta, 1739(2-3):331-354, (2005). [cited by applicant]
Chen et al., “Compromised function of the ESCRT pathway promotes endolysomal escape of tau seeds and propagation of tau aggregation,” J. Biol. Chem., 294(50):18952-18966, (2019). [cited by applicant]
Chen et al., “Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis,” Cell, 160(6):1246-1260 plus supplementary materials, (2015). [cited by applicant]
Chiu et al., “Identification of Calcium and Integrin-Binding Protein 1 as a Novel Regulator of Production of Amyloid β Peptide Using CRISPR/Cas9-based Screening System,” FASEB J., 34(6):7661-7674, (2020). [cited by applicant]
Cox, et al., “Banf1 is required to maintain the self-renewal of both mouse and human embryonic stem cells,” J. Cell Sci., 124(15):2654-2665, (2011). [cited by applicant]
Croft et al., “rAAV-based brain slice culture models of Alzheimer's and Parkinson's disease inclusion pathologies,” J. Exp. Med., 216(3):539-555, (2019). [cited by applicant]
Eftekharzadeh et al., “Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer's Disease,” Neuron, 99(5):925-940, (2018). [cited by applicant]
Frost et al., “Lamin Dysfunction Mediates Neurodegeneration in Tauopathies,” Curr. Biol., 26(1):129-136, (2016). [cited by applicant]
Furman et al., “Sensitive Detection of Proteopathic Seeding Activity with FRET Flow Cytometry,” J. Vis. Exp., 106:e53205, pp. 1-12, (2015). [cited by applicant]
Goodwin et al., “Large-scale discovery of mouse transgenic integration sites reveals frequent structural variation and insertional mutagenesis,” Genome Res., 29(3): 494-505, (2019). [cited by applicant]
Gorjanacz et al., “Caenorhabditis elegans BAF-1 and its kinase VRK-1 participate directly in post-mitotic nuclear envelope assembly,” EMBO J., 26(1):132-143, (2007). [cited by applicant]
Gorjanacz, “LEM-4 promotes rapid dephosphorylation of BAF during mitotic exit,” Nucleus, 4(1):14-17, (2013). [cited by applicant]
Gratuze et al., “Insulin deprivation induces PP2A inhibition and tau hyperphosphorylation in hTau mice, a model of Alzheimer's disease-like tau pathology,” Sci. Rep., 7:46359, 13 pages, (2017). [cited by applicant]
Hall et al., “Modeling tauopathy: a range of complementary approaches,” Biochim. Biophys. Acta, 1739(2-3):224-239, (2005). [cited by applicant]
Hannan et al., “Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models,” J. Neurochem., 137(1):12-25, (2016). [cited by applicant]
Hart et al., “High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities,” Cell, 163(6):1515-1526, (2015). [cited by applicant]
Holmes et al., “Prion-like Properties of Tau Protein: The Importance of Extracellular Tau as a Therapeutic Target,” J. Biol. Chem., 289(29):19855-19861, (2014). [cited by applicant]
Holmes et al., “Proteopathic tau seeding predicts tauopathy in vivo,” Proc. Natl. Acad. Sci. U.S.A., 111(41):E4376-E4385, (2014). [cited by applicant]
Jamin et al., “Barrier to Autointegration Factor (BANF1): interwoven roles in nuclear structure, genome integrity, innate immunity, stress responses and progeria,” Curr. Opin. Cell Biol., 34:61-68, (2015). [cited by applicant]
Jamin et al., “Barrier to Autointegration Factor (BANF1): interwoven roles in nuclear structure, genome integrity, innate immunity, stress responses and progeria,” Curr. Opin. Cell Biol., 34:61-68, Author Manuscript, (2… [cited by applicant]
Joung et al., “Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening,” Nat. Protoc., 12(4):828-863, (2017). [cited by applicant]
Jucker et al., “Self-propagation of pathogenic protein aggregates in neurodegenerative diseases,” Nature, 501(7465):45-51, (2013). [cited by applicant]
Kampmann, “A CRISPR Approach to Neurodegenerative Diseases,” Trends Mol. Med., 23(6):483-485, (2017). [cited by applicant]
Kampmann, “CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine,” ACS Chem. Biol., 13(2):406-416, (2017). [cited by applicant]
Kaufman et al., “Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo,” Neuron, 92(4):796-812, (2016). [cited by applicant]
Kfoury et al., “Trans-cellular Propagation of Tau Aggregation by Fibrillar Species,” The Journal of Biological Chemistry, 287(23): 19440-19451, (2012). [cited by applicant]
Konermann et al., “Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex,” Nature, 517(7536):583-588 plus supplementary materials, (2015). [cited by applicant]
Kurreck et al., “Design of antisense oligonucleotides stabilized by locked nucleic acids,” Nucleic Acids Res., 30(9):1911-1918, (2002). [cited by applicant]
Lee et al., “Transgenic animal models of tauopathies,” Biochim.259, (2005). [cited by applicant]
Molitor et al., “Depletion of the protein kinase VRK1 disruptsand leads to BAF retention on mitotic chromosomes,” Mol. Biol. Cell, 25(6):891-903, (2014). [cited by applicant]
Nagai et al., “Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons,” Nat. Neurosci., 10(5):615-622, (2007). [cited by applicant]
Nathaniel et al., “Elucidating Cellular Trafficking Pathways Controlling Prion-like Spread of Tau Aggregation Using CRISPR Interference Screens [abstract],” Abstracts; Poster Presentations, Cell Biology 2016, ASCB Annua… [cited by applicant]
Nicholls et al., “Characterization of TauC3 antibody and demonstration of its potential to block tau propagation,” PLOS ONE, 12(5):e0177914, 11 pages, (2017). [cited by applicant]
Nobuhara et al., “Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro,” Am. J. Pathol., 187(6):1399-1412, (2017). [cited by applicant]
Park et al., “A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors,” Nat. Genet., 49(2):193-203 plus online methods, (2017). [cited by applicant]
Prissette, et al., “Disruption of nuclear envelope integrity as a possible initiating event in tauopathies,” Cell Reports 40, 111249, (Aug. 23, 2022). [cited by applicant]
Puente et al., “Exome Sequencing and Functional Analysis Identifies BANF1 Mutation as the Cause of a Hereditary Progeroid Syndrome,” Am. J. Hum. Genet., 88(5):650-656, (2011). [cited by applicant]
Reczek et al., “A CRISPR screen identifies a pathway required for paraquat-induced cell death,” Nat. Chem. Biol., 13(12):1274-1279 plus online methods, (2017). [cited by applicant]
Samson et al., “Structural analysis of the ternary complex between lamin A/C, BAF and emerin identifies an interface disrupted in autosomal recessive progeroid diseases,” Nucleic Acids Res., 46(19):10460-10473, (2018). [cited by applicant]
Sanjana et al., “Improved vectors and genome-wide libraries for CRISPR screening,” Nat. Methods, 11(8):783-784, (2014). [cited by applicant]
Shalem et al., “Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells,” Science, 343:84-87 and Supplementary Material, (2014). [cited by applicant]
Simic et al., “Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies,” Biomolecules, 6(1):6, 28 pages, (2016). [cited by applicant]
Skotte et al., “Integrative Characterization of the R6/2 Mouse Model of Huntington's Disease Reveals Dysfunctional Astrocyte Metabolism,” Cell Rep., 23(7):2211-2224, (2018). [cited by applicant]
Snyers, et al., “LEM4/ANKLE-2 deficiency impairs post-mitotic re-localization of BAF, LAP2α and LaminA to the nucleus, causes nuclear envelope instability in telophase and leads to hyperploidy in HeLa cells,” Eur. J. Ce… [cited by applicant]
Tzelepis et al., “A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia,” Cell Reports, 17:1193-1205, (2016). [cited by applicant]
Wang et al., “Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras,” Cell, 168(5):890-903 plus supplemental materials, (2017). [cited by applicant]
Wang et al., “Identification and characterization of essential genes in the human genome,” Science, 350(6264):1096-1101, (2015). [cited by applicant]
Wolfe et al., “Tau Mutations in Neurodegenerative Diseases,” J. Biol. Chem., 284(10):6021-6025, (2009). [cited by applicant]
Yoshiyama et al., “Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model,” Neuron, 53(3):337-351, (2007). [cited by applicant]
Zhu et al., “Protein Phosphatase 2A Facilitates Axonogenesis by Dephosphorylating CRMP2,” The Journal of Neuroscience, 30(10):3839-3848, (2010). [cited by applicant]
EP Application 20735760.9 Communication pursuant to Article 94(3) EPC mailed Oct. 4, 2023. [cited by applicant]
EP Application 20735760.9 Intention to Grant mailed Jul. 11, 2024. [cited by applicant]
U.S. Appl. No. 16/900,432, Non-Final Office Action mailed Jan. 12, 2023. [cited by applicant]
U.S. Appl. No. 16/900,432, Notice of Allowance mailed Aug. 7, 2023. [cited by applicant]
U.S. Appl. No. 16/900,432, Requirement for Restriction/Election mailed Jul. 12, 2022. [cited by applicant]
U.S. Appl. No. 18/502,516, 2nd Corrected Notice of Allowance mailed Sep. 16, 2024. [cited by applicant]
U.S. Appl. No. 18/502,516, Notice of Allowance mailed Jun. 5, 2024. [cited by applicant]
U.S. Appl. No. 18/502,516, Notice of Allowance mailed Jun. 27, 2024. [cited by applicant]
WIPO Application No. PCT/US2020/037533, PCT International Search Report and Written Opinion of the International Searching Authority mailed Sep. 28, 2020. [cited by applicant]